Progression pattern and post‐progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma
Liver International · 2024
DOI: 10.1111/liv.15825 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, 2024. Verfasst von Satoshi Kobayashi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: the Kanagawa Prefectural Cancer foundation.
Abstract (Originalsprache)
Background
Although the combination of atezolizumab and bevacizumab (ATZ + BEV) is a standard treatment for advanced hepatocellular carcinoma (HCC), strategies for addressing treatment failure and prognostic factors of post‐progression survival (PPS) remain unestablished.
Methods
We conducted a multicentre retrospective study to evaluate PPS following ATZ + BEV treatment in patients with advanced HCC. We classified the patients into three groups: BCLC stage B and BCLC stage C without or with new extrahepatic lesions (BCLCp‐C1 and BCLCp‐C2, respectively) at the time of progression.
Results
Of the 204 patients who started ATZ + BEV treatment between October 2020 and September 2022, 110 showed disease progression, with 33, 55 and 22 showing the BCLCp‐B, BCLCp‐C1 and BCLCp‐C2 stages of the disease, respectively. Specifically, patients with the BCLCp‐B stage of the disease showed better overall survival than those with the BCLCp‐C1 and BCLCp‐C2 stages (hazard ratios: 1.93 [95% confidence interval, CI, 1.06–3.51] and 2.64 [95% CI, 1.32–5.30] for HCC stages BCLCp‐C1 and BCLCp‐C2, respectively). Via multivariable analysis, we identified the BCLCp‐C1 and BCLCp‐C2 stages, as well as performance status, Child–Pugh class and alpha‐fetoprotein as poor prognostic factors for PPS.
Conclusions
BCLCp‐B1 stage was identified as a better prognostic factor for PPS following ATZ + BEV treatment compared with BCLCp‐C1 and BCLCp‐C2 stages. This may help in making decisions regarding subsequent treatment after ATZ + BEV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
- Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
- Department of Gastroenterology, Tokai University School of Medicine, Isehara, Japan.
- Department of Gastroenterology, St. Marianna University School of Medicine, Kawasaki, Japan.
- Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
- Department of Gastroenterology, Yokohama City University, Yokohama, Japan.
ORCID-Profile: Satoshi Kobayashi, Tatehiro Kagawa, Haruki Uojima
Förderung
- the Kanagawa Prefectural Cancer foundation
Zitieren
APA
Kobayashi, S., Fukushima, T., Ueno, M., Chuma, M., Numata, K., Tsuruya, K., Arase, Y., Hirose, S., Kagawa, T., Hattori, N., Watanabe, T., Matsunaga, K., Uojima, H., Hidaka, H., Kusano, C., Morimoto, M., & Maeda, S. (2024). Progression pattern and post‐progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma. Liver International. https://doi.org/10.1111/liv.15825
Vancouver
Kobayashi S, Fukushima T, Ueno M, Chuma M, Numata K, Tsuruya K, et al. Progression pattern and post‐progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma. Liver International. 2024. doi:10.1111/liv.15825
BibTeX
@article{Kobayashi2024,
author = {Kobayashi, Satoshi and Fukushima, Taito and Ueno, Makoto and Chuma, Makoto and Numata, Kazushi and Tsuruya, Kota and Arase, Yoshitaka and Hirose, Shunji and Kagawa, Tatehiro and Hattori, Nobuhiro and Watanabe, Tsunamasa and Matsunaga, Kotaro and Uojima, Haruki and Hidaka, Hisashi and Kusano, Chika and Morimoto, Manabu and Maeda, Shin},
title = {Progression pattern and post‐progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15825}
}
EUVIMED